The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
Open accessAbstract
Disability accrual in multiple sclerosis may occur as relapse-associated worsening or progression independent of relapse activity. The role of progression independent of relapse activity in early multiple sclerosis is yet to be established. The objective of this multicentre, observational, retrospective cohort study was to investigate the contribution of relapse-associated worsening and progression independent of relapse activity to confirmed disability accumulation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, assessed within one year from onset and with follow-up ≥5 years (n = 5169). Data were extracted from the Italian Multiple Sclerosis Register. Confirmed disability accumulation was defined by an increase in Expanded Disability Status Scale score confirmed at 6 months, and classified per temporal association with relapses. Factors associated with progression independent of relapse activity and relapse-associated worsening were assessed using multivariable Cox regression models. Over a follow-up period of 11.5 ± 5.5 years, progression independent of relapse activity occurred in 1427 (27.6%) and relapse-associated worsening in 922 (17.8%) patients. Progression independent of relapse activity was associated with older age at baseline [hazard ratio (HR) = 1.19; 95% confidence interval (CI) 1.13–1.25, P < 0.001], having a relapsing–remitting course at baseline (HR = 1.44; 95% CI 1.28–1.61, P < 0.001), longer disease duration at baseline (HR = 1.56; 95% CI 1.28–1.90, P < 0.001), lower Expanded Disability Status Scale at baseline (HR = 0.92; 95% CI 0.88–0.96, P < 0.001) and lower number of relapses before the event (HR = 0.76; 95% CI 0.73–0.80, P < 0.001). Relapse-associated worsening was associated with younger age at baseline (HR = 0.87; 95% CI 0.81–0.93, P < 0.001), having a relapsing–remitting course at baseline (HR = 1.55; 95% CI 1.35–1.79, P < 0.001), lower Expanded Disability Status Scale at baseline (HR = 0.94; 95% CI 0.89–0.99, P = 0.017) and a higher number of relapses before the event (HR = 1.04; 95% CI 1.01–1.07, P < 0.001). Longer exposure to disease-modifying drugs was associated with a lower risk of both progression independent of relapse activity and relapse-associated worsening (P < 0.001). This study provides evidence that in an early relapsing-onset multiple sclerosis cohort, progression independent of relapse activity was an important contributor to confirmed disability accumulation. Our findings indicate that insidious progression appears even in the earliest phases of the disease, suggesting that inflammation and neurodegeneration can represent a single disease continuum, in which age is one of the main determinants of disease phenomenology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
Self-citationInflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
Sucksdorff, M., Matilainen, M., Tuisku, J., Polvinen, E., Vuorimaa, A., Rokka, J., Nylund, M., Rissanen, E., & Airas, L. (2020) · Brain · doi:10.1093/brain/awaa275 · Cited by 142
Cited by
Tur, C., Carbonell-Mirabent, P., Cobo-Calvo, Á., Otero-Romero, S., Arrambide, G., Midaglia, L., Castilló, J., Vidal-Jordana, Á., Rodríguez-Acevedo, B., Zabalza, A., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4655 · Cited by 273
Metadata
- Authors
- Portaccio, E., Bellinvia, A., Fonderico, M., Pastò, L., Razzolini, L., Totaro, R., Spitaleri, D., Lugaresi, A., Cocco, E., Onofrj, M., Di Palma, F., Patti, F., Maimone, D., Valentino, P., Confalonieri, P., Protti, A., Sola, P., Lus, G., Maniscalco, G. T., Brescia Morra, V., Salemi, G., Granella, F., Pesci, I., Bergamaschi, R., Aguglia, U., Vianello, M., Simone, M., Lepore, V., Iaffaldano, P., Filippi, M., Trojano, M., & Amato, M. P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-03-24
- Volume
- 145
- Issue
- 8
- Pages
- 2796-2805
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4220973510
- Cited by
- 163
- References
- 6
- FWCI
- 17.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.